简报:一项评估AMG 557在系统性红斑狼疮合并活动性狼疮关节炎患者中疗效的随机、双盲、平行组、安慰剂对照、多剂量研究
第169天狼疮关节炎缓解指数应答AMG 557组3/10 vs 安慰剂组1/10(P=0.58),SLEDAI评分改善≥4分者AMG 557组7/10 vs 安慰剂组2/10(P=0.07)。结论认为AMG 557显示安全性和潜在疗效,支持进一步评估ICOSL阻断在SLE患者中的临床疗效。
要点
- AMG 557 210 mg组与安慰剂组不良事件发生率相似,多数为轻度。
- 第169天狼疮关节炎缓解指数应答AMG 557组3/10 vs 安慰剂组1/10(P=0.58)。
- 第169天SLEDAI评分改善≥4分者AMG 557组7/10 vs 安慰剂组2/10(P=0.07)。
核心结论
- AMG 557显示出安全性和潜在疗效,支持进一步评估ICOSL阻断在SLE患者中的临床疗效。
研究设计与样本
- Ib期随机、双盲、平行组、安慰剂对照、多剂量研究,纳入系统性红斑狼疮合并关节炎患者,AMG 557 210 mg组10例、安慰剂组10例,每周1次共3周后每2周1次共10次追加剂量。
主要发现
- 不良事件发生率组间相似,多数为轻度。
- 狼疮关节炎缓解指数应答AMG 557组3/10 vs 安慰剂组1/10(P=0.58)。
- 第169天SLEDAI评分改善≥4分者AMG 557组7/10 vs 安慰剂组2/10(P=0.07)。
- 第169天全球BILAG指数评分较基线变化AMG 557组-36.3% vs 安慰剂组-24.7%。
- 第169天SLEDAI评分较基线变化AMG 557组-47.8% vs 安慰剂组-10.7%,压痛关节数变化-22.8% vs -13.5%,肿胀关节数变化-62.1% vs -7.8%。
关键数值与推荐
- 主要终点为第169天的安全性、免疫原性、狼疮关节炎缓解指数(LARI,定义为压痛和肿胀关节数减少)、英国狼疮评估组(BILAG)指数肌肉骨骼领域≥1个字母的改善以及停药情况。
- 次要/探索性终点为压痛和肿胀关节数、BILAG指数评分(肌肉骨骼、总体)和系统性红斑狼疮疾病活动指数(SLEDAI)的变化。
- 第85天皮质类固醇剂量减至≤7.5 mg/天,第29天停用免疫抑制剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and potential efficacy of AMG 557, a fully human antibody directed against the inducible T cell costimulator ligand (ICOSL) in patients with systemic lupus erythematosus (SLE) with arthritis. METHODS: In this phase Ib, randomized, double-blind, placebo-controlled study, patients received AMG 557 210 mg (n = 10) or placebo (n = 10) weekly for 3 weeks, then every other week for 10 additional doses. The corticosteroid dosage was tapered to ≤7.5 mg/day by day 85, and immunosuppressants were discontinued by day 29. Primary end points on day 169 were safety, immunogenicity, the Lupus Arthritis Response Index (LARI; defined by a reduction in the tender and swollen joint counts), ≥1-letter improvement in the musculoskeletal domain of the British Isles Lupus Assessment Group (BILAG) index, and medication discontinuation. The secondary/exploratory end points were changes in the tender and swollen joint counts, BILAG index scores (musculoskeletal, global), and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). RESULTS: The incidence of adverse events, most of which were mild, was similar between groups. LARI responses occurred in 3 of 10 patients receiving AMG 557 and 1 of 10 patients receiving placebo (P = 0.58). More patients in the AMG 557 group achieved a ≥4-point improvement in the SLEDAI score on day 169 (7 of 10 patients) compared with the placebo group (2 of 10 patients) (P = 0.07). Patients treated with AMG 557 (versus placebo) had greater improvements from baseline in the global BILAG index scores (-36.3% versus -24.7%) and the SLEDAI score (-47.8% versus -10.7%) and in tender (-22.8% versus -13.5%) and swollen (-62.1% versus -7.8%) joint counts on day 169. CONCLUSION: AMG 557 showed safety and potential efficacy, supporting further evaluation of the clinical efficacy of ICOSL blockade in patients with SLE.
引用
- Cheng LE, Amoura Z, Cheah B, et al. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Arthritis Rheumatol. 2018. PMID: 29513931. doi:10.1002/art.40479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。